[关键词]
[摘要]
目的 探讨莪术奥酮二醇(zedoarondiol,Zed)抑制白细胞介素-1β(interleukin-1β,IL-1β)诱导的巨噬细胞样血管平滑肌细胞(vascular smooth muscle cells,VSMCs)表型转化的作用及分子机制。方法 构建大鼠腹主动脉球囊损伤模型,设置对照组、模型组、Zed(20 mg/kg)组、普伐他汀(10 mg/kg)组和Zed+甲基-β-环糊精(methyl-β-cyclodextrin,MβCD,20 mg/kg)组,尾iv给药4周后,取腹主动脉,通过苏木素-伊红染色观察血管新生内膜面积与中膜面积比值变化,免疫组化法检测VSMCs表型标记物的表达。体外采用IL-1β建立巨噬细胞样大鼠冠状动脉平滑肌细胞表型模型,给予药物干预后,采用Transwell实验检测VSMCs迁移能力,免疫荧光染色观察α-平滑肌肌动蛋白(α-smooth muscle actin,α-SMA)、CD68的表达及细胞表型变化,ELISA检测胶原、基质金属蛋白酶及炎症因子的水平,qRT-PCR和Western blotting检测VSMCs表型相关基因和蛋白的表达。结果 动物实验结果显示,与模型组比较,Zed可显著降低大鼠腹主动脉球囊损伤后的血管新生内膜面积与中膜面积比值(P<0.01),上调平滑肌肌球蛋白重链(smooth-muscle myosin heavy chain,SM-MHC)表达(P<0.01),下调S100钙结合蛋白A4(S100 calcium-binding protein A4,S100A4)的表达(P<0.01);给予小窝蛋白-1(caveolin-1,Cav-1)抑制剂MβCD干预后,可逆转Zed对血管内膜增生及表型标记物SM-MHC、S100A4的调控作用(P<0.01)。细胞实验结果显示,IL-1β显著增强VSMCs迁移能力(P<0.01),上调促炎黏附因子、促炎趋化因子、促炎细胞因子、基质金属蛋白酶水平(P<0.01),下调收缩表型标志蛋白α-SMA、SM-MHC表达(P<0.01),诱导VSMCs向巨噬细胞样表型转化;Zed干预后可降低炎症因子与基质金属蛋白酶表达(P<0.05、0.01),提升胶原含量及收缩表型蛋白表达(P<0.01),抑制VSMCs异常表型转化。进一步机制研究显示,过表达Krüppel样因子4(Krüppel-like factor 4,KLF4)或沉默Cav-1可显著逆转Zed对VSMCs的巨噬细胞样表型转化作用(P<0.05、0.01)。结论 Cav-1与KLF4均是Zed发挥保护作用的必要分子,Zed可抑制IL-1β诱导的巨噬细胞样VSMCs表型转化与炎症反应,减轻血管内膜增生,提高胶原含量。
[Key word]
[Abstract]
Objective To investigate the effect and mechanism of zedoarondiol (Zed) in inhibiting interleukin-1β (IL-1β)-induced phenotypic transformation of macrophage-like vascular smooth muscle cells (VSMCs). Methods A rat abdominal aortic balloon injury model was established. Control group, model group, Zed (20 mg/kg) group, pravastatin (10 mg/kg) group and Zed + methyl-β-cyclodextrin (MβCD, 20 mg/kg) group were set up. After four weeks of tail iv administration, the abdominal aorta was taken and the ratio of neointimal area to media area was observed by hematoxylin-eosin staining. The expressions of VSMC phenotype markers were detected by immunohistochemistry. In vitro, a macrophage-like rat coronary artery smooth muscle cell phenotype model was established using IL-1β. After drug intervention, the migration ability of VSMCs was detected by Transwell assay, the expressions and phenotype changes of α-smooth muscle actin (α-SMA) and CD68 were observed by immunofluorescence staining. The levels of collagen, matrix metalloproteinases and inflammatory factors were detected by ELISA, the expressions of phenotype-related genes and proteins in VSMCs was detected by qRT-PCR and Western blotting. Results Animal experiment results showed that compared with model group, Zed significantly reduced the ratio of neointimal area to media area in abdominal aorta of rat after balloon injury (P < 0.01), upregulated the expression of smooth muscle myosin heavy chain (SM-MHC) (P < 0.01), and downregulated the expression of S100 calcium binding protein A4 (S100A4) (P < 0.01). After intervention with caveolin-1 (Cav-1) inhibitor MβCD, the regulatory effects of Zed on vascular intimal hyperplasia and phenotype markers SM-MHC and S100A4 were reversed (P < 0.01). The cell experiment results showed that IL-1β significantly enhanced the migration ability of VSMCs (P < 0.01), upregulated the levels of pro-inflammatory adhesion factors, pro-inflammatory chemokines, pro-inflammatory cytokines and matrix metalloproteinases (P < 0.01), downregulated the expressions of contraction phenotype marker proteins α-SMA and SM-MHC (P < 0.01), and induced VSMCs to transform into macrophage-like phenotype. Zed intervention could reduce the expressions of inflammatory factors and matrix metalloproteinases (P < 0.05, 0.01), increase collagen content and contractile phenotype protein expressions (P < 0.01), and inhibit abnormal phenotype transformation of VSMCs. Further mechanistic studies showed that Krüppel-like factor 4 (KLF4) overexpression or Cav-1 silencing significantly reverse the protective effect of Zed on VSMCs phenotypic transformation (P < 0.05, 0.01). Conclusion Both Cav-1 and KLF4 are essential molecules for Zed to exert its protective effects. Zed could inhibit IL-1β-induced phenotypic transformation and inflammatory response of macrophage-like VSMCs, reduce vascular intimal hyperplasia, increase collagen content.
[中图分类号]
R285.5
[基金项目]
国家自然科学青年基金项目(82104668); 中国中医科学院优秀青年科技人才(创新类)培养专项(ZZ14-YQ-009); 山西省中医药管理局科研项目(2022ZYYC032)